179 related articles for article (PubMed ID: 35204775)
1. APR-246-The Mutant TP53 Reactivator-Increases the Effectiveness of Berberine and Modified Berberines to Inhibit the Proliferation of Pancreatic Cancer Cells.
McCubrey JA; Abrams SL; Steelman LS; Cocco L; Ratti S; Martelli AM; Lombardi P; Gizak A; Duda P
Biomolecules; 2022 Feb; 12(2):. PubMed ID: 35204775
[TBL] [Abstract][Full Text] [Related]
2. Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53.
Abrams SL; Duda P; Akula SM; Steelman LS; Follo ML; Cocco L; Ratti S; Martelli AM; Montalto G; Emma MR; Cervello M; Rakus D; Gizak A; McCubrey JA
Cells; 2022 Feb; 11(5):. PubMed ID: 35269416
[TBL] [Abstract][Full Text] [Related]
3. Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines in the presence and absence of WT-TP53.
Abrams SL; Akula SM; Steelman LS; Follo ML; Cocco L; Ratti S; Martelli AM; Libra M; Falzone L; Candido S; Montalto G; Cervello M; Lombardi P; McCubrey JA
Adv Biol Regul; 2022 Jan; 83():100840. PubMed ID: 34866036
[TBL] [Abstract][Full Text] [Related]
4. Abilities of berberine and chemically modified berberines to interact with metformin and inhibit proliferation of pancreatic cancer cells.
Akula SM; Candido S; Libra M; Abrams SL; Steelman LS; Lertpiriyapong K; Ramazzotti G; Ratti S; Follo MY; Martelli AM; Murata RM; Rosalen PL; Bueno-Silva B; Matias de Alencar S; Montalto G; Cervello M; Gizak A; Rakus D; Mao W; Lin HL; Lombardi P; McCubrey JA
Adv Biol Regul; 2019 Aug; 73():100633. PubMed ID: 31047842
[TBL] [Abstract][Full Text] [Related]
5. Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticals.
Candido S; Abrams SL; Steelman LS; Lertpiriyapong K; Martelli AM; Cocco L; Ratti S; Follo MY; Murata RM; Rosalen PL; Bueno-Silva B; de Alencar SM; Lombardi P; Mao W; Montalto G; Cervello M; Rakus D; Gizak A; Lin HL; Libra M; Akula SM; McCubrey JA
Adv Biol Regul; 2019 May; 72():22-40. PubMed ID: 30898612
[TBL] [Abstract][Full Text] [Related]
6. TP53/miR-34a-associated signaling targets
Akula SM; Ruvolo PP; McCubrey JA
Aging (Albany NY); 2020 Jan; 12(3):2777-2797. PubMed ID: 31986125
[TBL] [Abstract][Full Text] [Related]
7. Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties.
McCubrey JA; Meher AK; Akula SM; Abrams SL; Steelman LS; LaHair MM; Franklin RA; Martelli AM; Ratti S; Cocco L; Barbaro F; Duda P; Gizak A
Aging (Albany NY); 2022 Apr; 14(8):3365-3386. PubMed ID: 35477123
[TBL] [Abstract][Full Text] [Related]
8. Small-Molecule MMRi62 Induces Ferroptosis and Inhibits Metastasis in Pancreatic Cancer via Degradation of Ferritin Heavy Chain and Mutant p53.
Li J; Lama R; Galster SL; Inigo JR; Wu J; Chandra D; Chemler SR; Wang X
Mol Cancer Ther; 2022 Apr; 21(4):535-545. PubMed ID: 35131878
[TBL] [Abstract][Full Text] [Related]
9. Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression.
McCubrey JA; Yang LV; Abrams SL; Steelman LS; Follo MY; Cocco L; Ratti S; Martelli AM; Augello G; Cervello M
Cells; 2022 Jul; 11(14):. PubMed ID: 35883598
[TBL] [Abstract][Full Text] [Related]
10. Sensitivity of pancreatic cancer cells to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals can be regulated by WT-TP53.
Abrams SL; Akula SM; Martelli AM; Cocco L; Ratti S; Libra M; Candido S; Montalto G; Cervello M; Gizak A; Rakus D; Steelman LS; McCubrey JA
Adv Biol Regul; 2021 Jan; 79():100780. PubMed ID: 33451973
[TBL] [Abstract][Full Text] [Related]
11. ABCC3 is a novel target for the treatment of pancreatic cancer.
Adamska A; Ferro R; Lattanzio R; Capone E; Domenichini A; Damiani V; Chiorino G; Akkaya BG; Linton KJ; De Laurenzi V; Sala G; Falasca M
Adv Biol Regul; 2019 Aug; 73():100634. PubMed ID: 31053501
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory Response to CK II Inhibitor Silmitasertib and CDKs Inhibitor Dinaciclib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines.
Ma Y; Sender S; Sekora A; Kong W; Bauer P; Ameziane N; Krake S; Radefeldt M; Al-Ali R; Weiss FU; Lerch MM; Parveen A; Zechner D; Junghanss C; Murua Escobar H
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457227
[TBL] [Abstract][Full Text] [Related]
13. A novel hotspot and rare somatic mutation p.A138V, at TP53 is associated with poor survival of pancreatic ductal and periampullary adenocarcinoma patients.
Saha G; Singh R; Mandal A; Das S; Chattopadhyay E; Panja P; Roy P; DeSarkar N; Gulati S; Ghatak S; Ghosh S; Banerjee S; Roy B; Ghosh S; Chaudhuri D; Arora N; Biswas NK; Sikdar N
Mol Med; 2020 Jun; 26(1):59. PubMed ID: 32552660
[TBL] [Abstract][Full Text] [Related]
14. Distinct mechanisms of innate and adaptive immune regulation underlie poor oncologic outcomes associated with KRAS-TP53 co-alteration in pancreatic cancer.
Datta J; Bianchi A; De Castro Silva I; Deshpande NU; Cao LL; Mehra S; Singh S; Rafie C; Sun X; Chen X; Dai X; Colaprico A; Sharma P; Dosch AR; Pillai A; Hosein PJ; Nagathihalli NS; Komanduri KV; Wilson JM; Ban Y; Merchant NB
Oncogene; 2022 Jul; 41(28):3640-3654. PubMed ID: 35701533
[TBL] [Abstract][Full Text] [Related]
15. Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals.
Abrams SL; Lertpiriyapong K; Yang LV; Martelli AM; Cocco L; Ratti S; Falasca M; Murata RM; Rosalen PL; Lombardi P; Libra M; Candido S; Montalto G; Cervello M; Steelman LS; McCubrey JA
Adv Biol Regul; 2018 Aug; 69():16-34. PubMed ID: 29980405
[TBL] [Abstract][Full Text] [Related]
16.
Maddalena M; Mallel G; Nataraj NB; Shreberk-Shaked M; Hassin O; Mukherjee S; Arandkar S; Rotkopf R; Kapsack A; Lambiase G; Pellegrino B; Ben-Isaac E; Golani O; Addadi Y; Hajaj E; Eilam R; Straussman R; Yarden Y; Lotem M; Oren M
Proc Natl Acad Sci U S A; 2021 Jun; 118(23):. PubMed ID: 34088837
[TBL] [Abstract][Full Text] [Related]
17. Docosahexaenoic acid inhibits the proliferation of Kras/TP53 double mutant pancreatic ductal adenocarcinoma cells through modulation of glutathione level and suppression of nucleotide synthesis.
Hung WC; Lee DY; Chiang EI; Syu JN; Chao CY; Yang MD; Tsai SY; Tang FY
PLoS One; 2020; 15(11):e0241186. PubMed ID: 33137095
[TBL] [Abstract][Full Text] [Related]
18. Chronic inflammation initiates multiple forms of K-Ras-independent mouse pancreatic cancer in the absence of TP53.
Swidnicka-Siergiejko AK; Gomez-Chou SB; Cruz-Monserrate Z; Deng D; Liu Y; Huang H; Ji B; Azizian N; Daniluk J; Lu W; Wang H; Maitra A; Logsdon CD
Oncogene; 2017 Jun; 36(22):3149-3158. PubMed ID: 27991926
[TBL] [Abstract][Full Text] [Related]
19. Abilities of berberine and chemically modified berberines to inhibit proliferation of pancreatic cancer cells.
Abrams SL; Follo MY; Steelman LS; Lertpiriyapong K; Cocco L; Ratti S; Martelli AM; Candido S; Libra M; Murata RM; Rosalen PL; Montalto G; Cervello M; Gizak A; Rakus D; Mao W; Lombardi P; McCubrey JA
Adv Biol Regul; 2019 Jan; 71():172-182. PubMed ID: 30361003
[TBL] [Abstract][Full Text] [Related]
20. Dose-Dependent AMPK-Dependent and Independent Mechanisms of Berberine and Metformin Inhibition of mTORC1, ERK, DNA Synthesis and Proliferation in Pancreatic Cancer Cells.
Ming M; Sinnett-Smith J; Wang J; Soares HP; Young SH; Eibl G; Rozengurt E
PLoS One; 2014; 9(12):e114573. PubMed ID: 25493642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]